Houston & Waltham, Mass.— Biostate AI, a leader in RNA sequencing-based artificial intelligence, has partnered with the nonprofit Accelerated Cure Project (ACP) to develop next-generation AI models aimed at predicting disease progression and treatment response in multiple sclerosis (MS).
As part of the collaboration, Biostate AI will analyze patient samples from ACP’s extensive biorepository—one of the world’s largest MS-specific collections of biospecimens and clinical data. The company will apply its proprietary barcode-integrated reverse transcription (BIRT) technology to produce high-resolution RNA profiles and train transformer-based AI models to personalize care for MS patients.
“Biostate’s RNA sequencing and AI technologies offer a unique opportunity to transform our understanding of MS progression and treatment response,” said Sara Loud, CEO of ACP. “We are thrilled to collaborate and unlock the full potential of our biorepository.”
ACP’s repository includes thousands of blood samples—many with longitudinal data—linked to detailed clinical and demographic information. The dataset provides a foundation for identifying molecular markers related to disease onset, relapse, remission, and response to therapy.
“By partnering with Biostate AI, we’re turning data into actionable insights that could revolutionize patient care,” said Dr. Stephanie Buxhoeveden, ACP’s Chief Scientific Officer.
Biostate plans to sequence the entire repository and develop a suite of AI tools addressing key clinical and research questions. These models aim to predict disease trajectories and identify which patients are most likely to benefit from specific therapies.
“Current MS management relies heavily on trial and error,” said David Zhang, Biostate AI co-founder and CEO. “By integrating RNA sequencing with AI, we aim to offer clinicians precise, data-driven guidance to accelerate and improve treatment decisions.”
This initiative marks Biostate AI’s expansion into neuroimmunology and supports its broader mission of developing disease-specific AI platforms powered by transcriptomic data.
“MS’s complexity and variability make it ideal for our approach,” said Ashwin Gopinath, Biostate AI co-founder and CTO. “Our goal is to create adaptable disease models that surpass conventional diagnostics.”
The partnership reinforces ACP’s focus on collaborative, data-driven research to advance cures, while expanding Biostate’s AI reach into areas with significant unmet clinical needs.
